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Neurophysiol 101: 2878-2888, 2009. First published March 18, 
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Excitatory GABA action induced by high [Cl-]i is thought
 to 
contribute to seizure generation in neonatal neurons although the 
mechanism of this effect remains unclear. We report that 
bumetanide, a NKCC1 antagonist, reduces driving force of GABA-
mediated currents (DFGABA) in neonatal hippocampal neurons and 
blocks the giant depolarizing potentials (GDPs), a spontaneous 
pattern of network activity. In the preparation composed of two 
intact interconnected hippocampi, bumetanide did not prevent 
generation of kainate-induced seizures, their propagation to the 
contralateral hippocampus, and formation of an epileptogenic mirror 
focus. However, in the isolated mirror focus, bumetanide effectively 
blocked spontaneous epileptiform activity transforming it to the 
GDP-like activity pattern. Bumetanide partially reduced DFGABA and 
therefore the excitatory action of GABA in epileptic neurons. 
Therefore bumetanide is a potent anticonvulsive agent although it 
cannot prevent formation of the epileptogenic mirror focus. We 
suggest that an additional mechanism other than NKCC1-mediated 
contributes to the persistent increase of DFGABA in epileptic neurons. 
 
 
INTRODUCTION 
 
GABA—the principal inhibitory neurotransmitter in adults—
excites immature neurons because of a higher [Cl-]i in different 
animal species and brain structures (Ben-Ari 2002).  
This difference is thought to play an important role in higher 
incidence of seizures early in life in humans (Hauser 1995; Moshe et 
al. 1983), lower seizure threshold in experimental animals, and 
higher neuronal excitability (Holmes and Ben-Ari 1998; Khazipov et 
al. 2004).  
This early elevated [Cl-]i is due to a sequential development of 
two chloride co-transporters: NKCC1, which imports chloride, and 
KCC2, which extrudes it (Kahle and Staley 2008a,b; Mikawa et al.  
2002; Shimizu-Okabe et al. 2002; Wang et al. 2002). Several 
observations suggest a link between the excitatory action of GABA 
and seizure generation at an early developmental stage (Dzhala and 
Staley 2003; Khazipov et al. 2004).  
Other observations suggest that bumetanide, a NKCC1 antagonist, 
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attenuates epileptiform activity in the immature rodent hippocampus 
by reducing [Cl-]i. The effects of bumetanide were observed neither 
in NKCC1 knock-out mice nor when GABA receptors were blocked, 
confirming the importance of [Cl-]i accumulation (Dzhala et al. 
2005). However, bumetanide was efficient against seizures acutely 
induced in vitro by some convulsants but not by others (Kilb et al. 
2007), indicating that in the latter case a NKCC1-independent 
mechanism was involved in seizure generation. Epilepsy is, 
however, a chronic disorder associated with permanent changes of 
several signaling cascades. Acute seizures models only partly reflect 
multiple events that occur in the epileptic network and are less 
relevant to the clinical situation.  
Excitatory actions of GABA have been reported in adult human 
epileptic temporal lobe neurons (Cohen et al. 2002; Huberfeld et al. 
2007) and in chronic epileptic foci in animal models (Khalilov et al. 
2003, 2005). Presumably, a gradual accumulation of intracellular 
chloride during recurrent seizures caused these GABA effects. It is 
therefore important to define a link between seizures, alterations in 
[Cl-]i, and epileptogenesis.  
We studied these issues in the intact interconnected hippocampal 
formation (IIHF). Using this preparation in a three-compartment 
chamber (Khalilov et al. 1999), we were able to initiate seizures in 
one hippocampus and then to investigate the effects of drugs on both 
the seizure propagation to other hippocampus and seizure-induced 
epileptogenic mirror focus formation (Khalilov et al. 2003, 2005) in 
that hippocampus.  
Our first aim was to investigate whether bumetanide acts as an 
antiepileptogenic agent and therefore prevents formation of the 
epileptogenic mirror focus by seizures. If this is not the case, 
bumetanide can still block seizures in the mirror focus and thus to 
cause an anticonvulsive effect.  
The second aim was to investigate the role of NKCC1 in an 
increased neuronal [Cl-]i in epileptogenic mirror foci.  
Because it recently has been shown that the invasive recordings 
provide inadequate measures of the resting membrane potential (Em) 
(Tyzio et al. 2003) and the perforated-patch technique may cause 
systematic errors in measurements of the reversal potential of 
GABA-induced currents (EGABA) (Brumback and Staley 2008), we 
used noninvasive single N-methyl-D-aspartate (NMDA) and GABA 
channel recordings to determine, respectively, Em and EGABA. 
 
METHODS 
Experiments were performed on neonatal Wistar rats (postnatal 
days P7–P8). All experiments have been carried out in accordance 
with the European Communities Council Directive of 24 November 
1986 (86/609/EEC). 
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 Hippocampal preparation  
 
The interconnected intact hippocampal formations were prepared 
as described previously (Khalilov et al. 1997 ). In brief, neonatal 
Wistar rats were decapitated after hypothermic anesthesia, and the 
brain rapidly removed to oxygenated (95% O2-5% CO2) ice-cold 
artificial cerebrospinal fluid (ACSF). Complexes including two 
interconnected hippocampi were isolated and transferred into a 
beaker with oxygenated ACSF containing (in mM) 126 NaCl, 3.5 
KCl, 2.0 CaCl2, 1.3 MgCl2, 25 NaHCO3, 1.2 NaH2PO4, and 11 
glucose (pH 7.4) and incubated 1 h before use. The intact 
hippocampal formations were placed into the conventional fully 
submerged three-compartment chamber (Fig. 3, see diagram) and 
superfused with oxygenated ACSF (30–32°C, 10–15 ml/min). The 
hippocampi were fixed by entomological needles to the silicone 
elastomer (Sylgard)-covered bottom. 
  
Slice preparation  
 
Slices were prepared as described previously (Ben-Ari et al. 
1989). In brief, after decapitation, the brain was rapidly removed and 
placed in oxygenated, ice-cooled ACSF; hippocampal transverse 
slices (500 µm) were cut with a McIIwain tissue chopper and kept in 
oxygenated ACSF at room temperature for 1 h before use. Individual 
slices were then transferred to the recording chamber where they 
were fully submerged and superfused with oxygenated ACSF (30–
32°C, 2–3 ml/min). 
 
Electrophysiological recordings  
 
All recordings were made from CA3 pyramidal layer. Whole cell 
patch-clamp recordings in voltage- or current-clamp configuration 
were collected using an Axopatch 200B amplifier (Axon 
Instruments). Patch pipette solution were: 1) for recordings of single 
GABA(A) channels containing (in mM) 120 NaCl, 20 TEA-Cl, 5 
KCl, 5 4-aminopyridine, 0.1 CaCl2, 10 MgCl2, 10 glucose, 10 
HEPES-NaOH buffered to pH 7.2–7.3 and 1 µM GABA; 2) for 
recordings of single NMDA channels: nominally Mg2+-free ACSF 
with 10 µM NMDA and 1 µM glycine; 3) for whole cell recordings 
(in mM): 140 CsCl, 1 CaCl2, 10 EGTA, 10 HEPES, 2 MgATP, and 
0.4 GTP, pH 7.25, osmolarity 280, patch pipettes had a resistance of 
8–10 M; 4) for gramicidin perforated-patch recording (in mM): 150 
KCl and 10 HEPES, buffered to pH 7.2 with Tris-OH. Gramicidin 
was first dissolved in DMSO to prepare a stock solution of 40 mg/ml 
and then diluted to a final concentration of 80 µg/ml in the pipette 
solution. The gramicidin-containing solution was prepared 30 min 
before the experiment. Patch pipettes were filled with a gramicidin-
containing solution, and then the tip was dipped into and filled with 
a gramicidin-free solution by applying a negative pressure for 30–40 
s to facilitate cell-attached formation (4–10 G). Twenty to 30 min 
after cell-attached formation, series resistance decreased and 
stabilized. At the end of each recording, negative pressure applied to 
break the membrane and establish whole cell configuration. This was 
associated with a shift of the reversal potential of the GABAA 
mediated responses to near 0 mV. Cells were identified by adding 
biocytin (0.4%) to the pipette solution for morphological analysis.  
Extracellular potentials were recorded using two types of 
electrodes: field recordings were made with glass micropipettes 
(GC120TF-10, Clark Electromedical Instruments) filled with ACSF 
(1–5 M); and to record multiunit activity (MUA), we used tungsten 
wire electrodes (diameter: 50 µm, California Fine Wire, Grover 
Beach, CA). Recording electrodes were positioned in a pyramidal 
cell layer of CA3 subfield, and signals were amplified using a 
custom-made DAM-8A amplifier (WPI, GB; low filter: 0.1 Hz; high 
filter: 3 kHz; x1,000). Electrical stimulations were made with a 
bipolar electrode (10–20 V, 40 µs).  
Synaptic responses were acquired using an A/D converter (Digidata 
1440A, Axon Instruments). Axoscope and Clampfit 10.1 (Axon 
Instruments) and Origin 7.0 (Microcal Software) programs were 
used for the acquisition and analysis of the synaptic activities. Group 
measures are expressed as means ± SD, error bars also indicate SD. 
Statistical significance of differences was assessed with the Student's 
t-test, the level of significance was set at P < 0.05. Drugs used were 
purchased from Sigma [tetrodotoxin (TTX), bumetanide, 
gramicidin], Tocris [bicuculline, gabazine, 6-cyano-7-
nitroquinoxaline-2,3 dione (CNQX), D-2-amino-5-
phosphopentanoate (APV)] and Molecular Probes (biocytin).  
 
RESULTS 
  
Bumetanide reduces the excitatory GABA action and blocks GDPs in 
naïve neurons 
 
We first tested the actions of bumetanide on activity of immature 
hippocampal neurons with simultaneous extracellular and gramicidin 
perforated patch-clamp recordings (Fig. 1). Neuronal activity at early 
developmental stages is characterized by spontaneous network-
driven discharges, so-called giant depolarizing potentials (GDPs) 
(Ben-Ari et al. 1989), consisting predominantly of GABAergic 
postsynaptic currents (PSCs) and bursts of MUA in field potential 
recordings (Fig. 1Aa). As in earlier observations (Sipila et al. 2006), 
bumetanide (10 µM) blocked spontaneous and evoked GDPs (Fig. 
1Ba). In control, single-electrical stimulation evoked a burst of 
action potentials and large GDPs (Fig. 1Aa). Addition of bumetanide 
strongly reduced both the number of action potentials (from 65.7 ± 
16.9 to 8 ± 2.6 spike, n = 17) and the amplitude of evoked PSCs(Fig. 
1, Ba and C). In the presence of APV (40 µM) and CNQX (10 µM), 
evoked PSCs were considerably reduced, but a few spikes (5.1 ± 1.7 
spike, n = 17) were still present (Fig. 1, Ab and C). These spikes 
were blocked by further addition of bicuculline (Fig. 1, Ac and C), 
confirming the contribution of excitatory GABAergic synapses in 
their generation. While bicuculline-sensitive spikes could be 
generated in the presence of glutamate receptors antagonists, they 
were not generated in the presence of bumetanide (Fig. 1Bb). 
Therefore bumetanide was as efficient as bicuculline in blocking the 
GABA-mediated spiking activity.  
Relying on I-V relations of single NMDA and GABA channels 
(Fig. 2A), we then determined the alterations in DFGABA produced by 
bumetanide. As shown in Fig. 2, B and C (left), bumetanide did not 
change Em (–78.5 ± 2.3 and –79.8 ± 3.2 mV, n = 9 and n = 13, 
respectively, P = 0.5). However, bumetanide decreased DFGABA 
(from 13.7 ± 11.6 to 2.02 ± 4.8 mV, n = 8 and n = 10, respectively, P 
< 0.01) and thus negatively shifted EGABA. Therefore bumetanide 
reduced [Cl-]i leading to a less depolarized DFGABA and blockade of 
GDPs.  
 
Bumetanide does not block generation and propagation of kainate-
induced seizures  
 
We then tested the effects of bumetanide on the generation and 
propagation of seizures induced by unilateral application of kainate 
using the IIHF in three-compartment chamber Fig. 3A (left). In 
keeping with our earlier observations (Khalilov et al. 2003), a single 
application of kainate (300–400 nM) generated recurrent ictal events 
that propagated from the kainate-treated hippocampus to the 
contralateral one (Fig. 3A). As shown in Fig. 3A (right), these 
paroxysmal discharges included high-frequency oscillations (HFOs; 
50–150 Hz) in both treated (not shown) and naïve hippocampi. As  
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long as the two hippocampi were connected, continuous application 
of bumetanide (10 µM) to the contralateral naïve hippocampus—in 
parallel with recurrent applications of kainate to the treated side—
did not reduce the severity of ictal events in both hippocampi as 
indicated by the HFOs (Fig. 3B, right) and power spectrum (Fig. 3D; 
n = 7). In fact, continuous application of bumetanide to both 
hippocampi while kainate was applied to one hemisphere also failed  
to reduce seizure severity in both kainate treated and contralateral 
side (not shown, n = 3). Higher concentrations of bumetanide (50 
µM) failed to reduce seizure severity (not shown, n = 3) as well.  
 
Bumetanide does not prevent formation of a mirror focus but blocks 
seizure generation in the mirror focus  
 
To form an epileptogenic mirror focus, we used recurrent 
applications of kainate (15 times) to one hippocampus (ipsilateral, 
ipsi-) that generated an epileptic focus in the connected hippocampus 
(contralateral, contra-) (Khalilov et al. 2003, 2005). With this 
protocol, naive hippocampus (contra-) became epileptic and 
generated seizures after disconnection from the kainate treated side 
for 2 days (Khalilov et al. 2003 , 2005 ). In these experiments, in 
parallel with recurrent kainate applications, bumetanide was 
continuously applied to the contralateral hippocampus. Following 
repeated applications of kainate, both hippocampi generated 
spontaneous and synchronous ictal-like seizures in spite of the 
presence of bumetanide (Fig. 4A). Interestingly, analyses of the 
inter-hemispheric latencies revealed that each spontaneous ictal 
event always originated initially from the ipsilateral hippocampus  
FIG. 1. Bumetanide blocks GABA-mediated 
excitation and GDPs in neonatal rat 
hippocampus. Dimultaneous extracellular and 
gramicidin-perforated patch-clamp recordings in 
the CA3 pyramidal layer of hippocampus in 
artificial cerebrospinal fluid (ACSF, A) and 
ACSF + bumetanide (Bum; B). Ab and Bb: 
similar recordings in the presence of 6-cyano-7-
nitroquinoxalene-2,3-dione (CNQX) and D-2-
amino-5-phosphopentanoate (APV). Note that 
glutamatergic receptor antagonists blocked 
100% of the evoked (arrows) multiunit activity 
(MUA) in the bumetanide treated slices and only 
90% in control. Ac and Bc: the remaining 
activity was completely blocked by the 
GABAergic receptor antagonist bicuculline 
(Bicu) confirming the excitatory action of 
GABA in naïve neurons. C: summary plot of the 
mean number of units evoked by a single 
stimulus (15–20 stimuli per slice) in 4 
independent experiments. 
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(Fig. 4Ab, n = 5) that was not the case during tonic-clonic and clonic 
phases of the event (Figs. 4A, c and d, n = 40).  
We then disconnected the two hippocampi by severing the 
commissural fibers (not shown) or by applying TTX to the 
commissural chamber (Fig. 4B) while the contralateral hippocampus 
was still exposed to bumetanide. We observed that seizures were 
generated in the kainate-treated hippocampus only. The bumetanide-
treated side failed to generate the epileptiform activity (Fig. 4B, n = 
4), generating instead the synchronized events reminiscent to GDPs 
(named further as epileptic GDPs, EGDPs). However, after washing 
out of bumetanide, spontaneous and evoked seizures reappeared 
(Fig. 4C). In additional experiments, continuous application of 
bumetanide to both hippocampi while kainate was repeatedly applied 
to only one, failed also to prevent the formation of epileptogenic foci 
in both hippocampi (n = 4, not shown). Therefore bumetanide 
prevented neither the long-term effects of kainate nor transformation 
by propagating seizures the naive hippocampus to one generating 
seizures.  
 
Bumetanide restores GDP-like recurrent population bursts in the 
mirror focus 
 
We then investigated the electrical properties of the disconnected 
mirror focus more detail. Field and patch-clamp recordings were 
made from the isolated mirror focus in intact hippocampi and in 
slices prepared from such hippocampus, which also were able to 
generate spontaneous epileptiform events (Khalilov et al. 2003). The 
isolated intact hippocampus generated spontaneously ictal and 
interictal events that were fully blocked by bumetanide (Fig. 5 A, n = 
7). Similar observations were made in slices prepared from the 
mirror foci (Fig. 5B, n = 9). In the presence of bumetanide, the 
disconnected mirror focus generated EGDPs (see following text and 
Fig. 6). Bumetanide also blocked the induction of stimuli-induced 
epileptiform oscillations in the mirror focus (not shown, n = 10).   
After washout, spontaneous and evoked epileptiform oscillations 
reappeared after various delays, suggesting that the permanent 
network alterations in the mirror focus were not abolished by 
bumetanide (Fig. 5B). Therefore bumetanide blocked seizure 
generation in the mirror focus but neither prevented formation of the 
mirror focus nor reversed the chronic epileptic features of the tissue.  
After addition of bumetanide, interictal activity was completely 
suppressed and replaced by recurrent population bursts of activity, 
EGDPs, that had a number of similar features with physiological 
patterns, GDPs, including (Fig. 6): both types of events were 
characterized by a few hundred millisecond increase in MUA with a 
relatively small delta-wave-like deflection of local field potentials in 
the pyramidal cell layer and without population spikes (Figs. 6Ba 
and 7A, *); both population events had much smaller amplitudes 
than those of interictal events (110 ± 18.9 mV for GDPs; 71.3 ± 1.2 
mV for EGDPs, and 553.2 ± 12.4 mV for interictal events, n = 24, n 
= 27, and n = 48 events, respectively, P < 0.01; Fig. 6D); in 
gramicidin perforated-patch recordings, both types of events had 
similar reversal potential (60.9 ± 3.1; 59.6 ± 1.5 mV, and 36.9 ± 4.6 
mV for interictal events, n = 10; Fig. 6, a and b); and estimated in 
cell-attached recordings, the number of spikes in CA3 pyramidal  
FIG. 2. Bumetanide strongly reduces the 
depolarizing driving force of GABA-mediated 
currents (DFGABA). A: cell-attached recordings 
of single GABA(A; left) and N-methyl-D-
aspartate (NMDA) receptor channels (right) in 
CA3 pyramidal cells in control ACSF. B: I-V 
relationships of single GABAA and NMDA 
receptor channels in ACSF ( ) and 
bumetanide-treated ( ) slices. C: summary plot 
of the resting membrane potential (Em) and 
driving force of GABA-mediated currents 
(DFGABA = EGABA – Em) in control ( ) and in 
bumetanide ( ). Each circle corresponds to 1 
CA3 pyramidal cell. Error bars indicate SD. 
 
2881 
  R. NARDOU,Y. BEN-ARI, AND I. KHALILOV 
 
J Neurophysiol - VOL 101 – JUNE 2009 – www.jn.org 
cells was similar during GDPs (Fig. 6Ac) and EGDPs (Cc) but much 
bigger during interictal (Bc) activity (1–2 spikes for control or 
EGDPs and 4–5 for interictals; Fig. 6E).  
Thus in spite of the fact that bumetanide eliminated epileptiform 
activity in the mirror focus some population activity, EGDPs, still 
remained, presumably due to a NKCC1-independent increase of [Cl-
]i in epileptic neurons. 
                                                                                                                                                                                                                                                     
NKCC1 underlies only partially excitatory GABA action in 
epileptogenic neurons  
 
Formation of the mirror focus is associated with a permanent 
increase in EGABA (Khalilov et al. 2003). This and other observations 
(Cohen et al. 2002; Fujiwara-Tsukamoto et al. 2007; Jin et al. 2005; 
Rivera et al. 2004; for review, see Ben-Ari et al. 2007) suggest that 
recurrent seizures produce a permanent accumulation of chloride and 
therefore enhance the excitatory action of GABA.  
As shown in Fig. 7, A–D, the excitatory actions of GABA in the 
mirror focus were reduced but not blocked by combined applications 
of bumetanide, APV, and CNQX. Bumetanide transformed stimuli-
induced epileptiform oscillations to EGDPs (Fig. 7, A and B). 
Evoked bursts of action potentials were still observed after 
application of APV and CNQX (Fig. 7C) and were completely 
blocked following application of bicuculline (D), suggesting that in
the presence of bumetanide, GABA still exerts an excitatory action 
mediated by NKCC1-independent mechanism(s).  
To clarify this effect, we measured Em and DFGABA in epileptic 
neurons. Em was not significantly different in naïve neurons and 
neurons (Fig. 7E) in the mirror focus (–78.1 ± 1.8 and –74,8 ± 2.3 
mV, n = 14 and n = 10, respectively, P = 0.08. 
Bumetanide or glutamate receptor antagonists (CNQX+APV) 
blocked seizures but did not alter Em. In neurons of epileptic mirror 
foci, however, DFGABA was significantly increased (from 13.2 ± 12.2  
FIG. 3. Bumetanide does not block generation and propagation of kainate-induced seizures. Left: experimental design and the 3-compartment chamber. Two 
hippocampi and commissural connections have independent inlets and a common outlet. Kainate was applied to 1 hippocampus [ipsilateral (ipsi-)] and 
electrical activity recorded in ipsi- and contralateral hippocampus (contra-). A: kainic acid (300–400 nM) was applied briefly (3 min) to 1 compartment (ipsi-), 
whereas the contralateral compartment was perfused with normal ACSF. Seizures induced in the ipsilateral hippocampus propagate to the contralateral side. 
High-frequency oscillations (HFOs, 50–150 Hz) were observed in the contralateral hippocampus. These high-frequency activities were visualized by time-
frequency (TF) representations using Wavelet analysis. Here field power is coded in colors so that red corresponds to higher frequency (right). B: kainate was 
applied to one hippocampus (ipsi-) and bumetanide (10 µM) to the naïve contralateral hippocampus (contra-). Bumetanide did not block ictal-like events and 
HFOs in the contralateral hippocampus (TF representations and power spectrogram). C: perforated-patch recordings from a neuron in the contralateral  
treatment (red trace). Cb: integral currents calculated from Ca. D: power spectrum of field potentials during ictal events in control and in the presence of 
bumetanide. 
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to 37.3 ± 8.1 mV, n = 8 and n = 33, respectively, P < 0.001) that 
resulted in a positive shift in EGABA (Fig. 7F). Bumetanide 
significantly reduced this shift (from 37.3 ± 8.1 to 14.2 ± 7.6 mV, n = 
33 and n = 17, respectively, P < 0.001), although values of DFGABA 
remained bigger than those in naïve neurons (14.2 ± 7.6 vs. 2.02 ± 
4.8 mV in naïve neurons in the presence of bumetanide; Figs. 7F and 
2C). Increasing the bumetanide concentration (50 µM, n = 8) or 
blockade of ongoing seizures by CNQX+APV failed to block this 
persistent increase of DFGABA.  
Therefore in the presence of bumetanide, DFGABA remained by 
10 mV bigger in the epileptic neurons comparing with those in 
control, and this difference was independent of ongoing epileptiform 
activity.  
 
DISCUSSION 
 
The principal finding of the present study is that bumetanide 
reduces DFGABA and blocks seizures in the mirror focus, suggesting 
that the excitatory action of GABA, mediated at large by NKCC1, is 
critically important for the generation of epileptiform activity. 
However, bumetanide does not prevent the seizure-dependent 
transformation of a naïve network to the epileptic one, suggesting 
that seizures beget seizures even when NKCC1 is not functioning. In 
addition, a residual increase in DFGABA in the presence of bumeta- 
FIG. 4.   Bumetanide does not prevent the formation of an 
epileptogenic mirror focus. A: simultaneous field 
recordings in the ipsilateral hippocampus exposed 15 times 
to kainate and contralateral hippocampus continuously 
exposed to bumetanide. Both hippocampi were connected 
and spontaneous seizures were synchronous. Aa: an 
epileptiform ictal-like activity depicted at larger scale. A, b 
and c: epileptiform events at the start and at the end (tonic-
clonic phase) of the ictal-like activity. Note that seizures 
originated always (n = 5) from ipsilateral hippocampus as 
shown in Ab at expended scale. During the tonic-clonic 
phase (Ac), this is not the case, as quantified in Ad. Ad: 
quantification of the inter-hemispheric latencies ( t). B 
and C: simultaneous field recordings following 
disconnection of 2 hemispheres by applying TTX onto 
commissural connections. B: bumetanide is still present in 
the contralateral side. Seizures are not generated; however, 
GDP-like population activity still exists. C: after washing 
bumetanide out, both sides generate seizures that are not 
synchronous. 
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nide indicates that a persistent elevation of [Cl-]i in the epileptic 
neurons is only partially mediated by NKCC1.  
 
Bumetanide is an anticonvulsive but not an antiepileptogenic agent  
 
The effects of bumetanide on seizures are quite controversial 
depending on the type of model and convulsive agent used. 
Bumetanide reduced seizures generated by high K+ (Dzhala et al. 
2005; Kilb et al. 2007), reduced (Dzhala et al. 2008) or increased 
(Kilb et al. 2007) seizures generated by low Mg2+, and augmented 
the frequency of seizures generated by kainate (Kilb et al. 2007). 
Delpire and colleagues (Zhu et al. 2008) suggested that NKCC1 
antagonists aggravate 4-aminopyridine-induced seizures and 
enhance neuronal excitability, albeit at a later developmental stage 
(P10–P13), and also suggested that NKCC1 actually reduces hyper-
excitability.  
We found that bumetanide neither reduced nor aggravated the 
severity of seizures in both kainate-treated hippocampus and 
contralateral hippocampus to which these seizures propagated and 
failed also to prevent formation of the epileptogenic mirror focus. 
Bumetanide did not block the high-frequency components of 
seizures (>40 Hz), which are critically important for the formation of 
mirror focus (Khalilov et al. 2005). It also did not alter GABA-
mediated PSCs during ictal events generated by the propagation of 
seizures from the kainate-treated hippocampus. In contrast, GABA 
receptor antagonists block the HFOs and mirror focus formation 
(Khalilov et al. 2005) confirming that functional GABA signaling is 
essential for these events.  
In spite of a DFGABA reduction by bumetanide in naïve neurons 
of to the levels close to Em, the dynamic accumulation of chloride 
during severe seizures is not fully controlled by NKCC1.  
Therefore it is likely that during recurrent seizures the severity of 
ictal events and the GABA-mediated massive influx of chloride 
overcome the inhibitory effect of bumetanide on NKCC1 and [Cl-]i 
accumulation. Dynamic effects of seizures on DFGABA, that is likely 
neuronal type dependent, and the mechanisms of chronic alteration 
of DFGABA by seizures remain to be further investigated.  
In contrast, bumetanide fully blocked generation of seizures in 
the disconnected mirror focus although the GDP-like pattern, 
EGDPs, still remained. Its properties, however, differed significantly 
from those of interictal events.  
Determining the mechanisms underlying the chronic alterations 
of [Cl-]i in epileptic tissues is important because most antiepileptic 
drugs (AEDs) have been developed using adult experimental models 
that do not possess the unique properties of immature neurons and 
networks (Connell et al. 1989; Painter et al. 1999; Staley 2008). It 
has been suggested that drugs that reduce [Cl-]i such as bumetanide 
may constitute a novel family of AEDs adapted to developmental 
epilepsies (Dzhala et al. 2008; Kahle and Staley 2008b). Our 
observations, however, suggest that although bumetanide blocks the 
expression of seizures, it may not be efficient in preventing the long-
lasting sequels of recurrent seizures. This is particularly important 
because seizures in neonates can cause long-lasting deteriorate 
effects (Ben-Ari 1985; Hauser et al. 1998; Levene 2002; Massingale 
and Buttross 1993; Mizrahi and Clancy 2000; Moshe and Albala 
1982; Tremblay et al. 1984). 
 
NKCC1 is partly responsible for the persistent increase of DFGABA in 
epileptic neurons  
 
Previous studies consistently showed that bumetanide reduces 
[Cl-]i and the excitatory actions of GABA in immature neurons 
(Dzhala et al. 2005; Sipila et al. 2006; Yamada et al. 2004). 
However, these studies used invasive recording techniques—whole 
FIG. 5. Bumetanide blocks seizures in the mirror 
focus. Field recordings in the separated 
contralateral intact hippocampus (A) and slices 
obtained from the contralateral hippocampus (B) 
after mirror focus formation. Note that seizures 
have been blocked by bumetanide and replaced 
by spontaneous (GDP-like) population events 
(see Fig. 6). 
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cell and perforated-patch recordings—that strongly alter resting 
membrane potential (Tyzio et al. 2003). Here we used for the first 
time single channel recordings to determine the actions of 
bumetanide on both Em and EGABA and thus the driving force of 
GABA DFGABA. Our results indicate that bumetanide clearly reduces 
significantly EGABA leading to an important fall in the driving force 
of GABA and confirming the actions of the diuretic compound on 
intracellular chloride and EGABA. The small change of Em in epileptic 
neurons when compared with controls as determined with single 
NMDA channel recordings may be due to tonic GABAA current 
(Sipila et al. 2005) that causes increased membrane depolarization 
due to depolarizing DFGABA. But we did not investigate further this 
issue. We also did not investigate possible distal actions of 
bumetanide on the dendrites of pyramidal neurons or on other 
neuronal populations.  
Enhancement of [Cl-]i in the mirror focus neurons was 
significantly reduced by bumetanide  
However, under action of bumetanide, DFGABA in the epileptic 
neurons was still bigger than in control (>10 and 2 mV, 
respectively). Although the upregulation of NKCC1 expression in 
epileptic mirror focus neurons cannot be excluded (Okabe et al. 
2002), the increase in bumetanide concentration has not reduced [Cl-
]i further, suggesting that other mechanisms are involved. One 
possible candidate is the KCC2 that is thought to play a fundamental 
role in Cl- extrusion (Hubner et al. 2001; Lee et al. 2005; Rivera et 
al. 1999). It is well documented that KCC2 expression in rodents is 
low at birth in the forebrain and increases steadily during the first 2–
3 wk of postnatal life (Clayton et al. 1998; Dzhala et al. 2005; Lu et 
al. 1999; Mikawa et al. 2002; Rivera et al. 1999; Wang et al. 2002). 
Seizures and other insults can induce a downregulation of KCC2 
expression (de et al. 2006; Fiumelli et al. 2005; Palma et al. 2006; 
Payne et al. 2003; Rivera et al. 2004).  
However, to the best of our knowledge, little information is 
available on the functionality of KCC2 at an early developmental 
stage. We cannot also exclude a participation of voltage-gated Cl- 
channels to the chloride homeostasis (Farrant and Kaila 2007; 
Huguenard and Alger 1986; Ling and Benardo 1995; McCarren and 
Alger 1985; Payne et al. 2003; Staley et al. 1996; Thompson and 
Gähwiler 1989).  
In conclusion, our study with the use of noninvasive single 
channel recordings in chronic epileptic tissue, confirms the 
importance of evaluation of DFGABA and Em to examine the effects of 
seizures and putative anticonvulsive agents on neuronal network 
functioning. Our observations are in favor of using bumetanide for 
blocking seizures in neonates but also call for studies of other 
regulators of intracellular chloride and their effects on seizures.  
Although a strict comparison with the clinical situation is 
difficult because of the large variety of epilepsy types and long-
lasting duration required for seizures to evoke their neurological 
sequels, we consider the mirror focus as an "epileptic" tissue because 
it generates spontaneously recurrent ictal and interictal seizures for 
hours and up to 2 days [the longest period this preparation could be 
kept (Khalilov et al. 2003)]. It has been suggested that a combination 
of phenobarbital and bumetanide is more efficient for treating 
refractory infantile epilepsies because bumetanide reduces DFGABA 
and phenobarbital augments the efficacy of inhibitory GABA  
FIG.. 6. Bumetanide transforms seizure 
activity into the GDP-like recurrent 
population bursts. Simultaneous extracellular 
and gramicidine perforated-patch recordings 
of spontaneous synchronized network activity 
in control slices (A), mirror focus slices (B), 
and mirror focus slices in the presence of 
bumetanide (C). Ab, Bb, and Cb: I-V relations 
of perforated-patch currents. Ac, Bc, and Cc: 
simultaneous extracellular and cell-attached 
recordings of spontaneous network activity in 
control, mirror focus slices, and mirror focus 
slices in the presence of bumetanide. D: 
summary plot of mean amplitudes of field 
potentials during synchronized network 
events. E: the mean number of cell-attached 
recorded spikes during this synchronized 
activity. 
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signaling (Dzhala et al. 2008; Kahle and Staley 2008b). The validity 
of this attractive hypothesis will depend, however, on the 
contribution of NKCC1 to positive DFGABA in epileptic conditions. 
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FIG. 7. Bumetanide reduces only partially the positive DFGABA in epileptogenic focus. A–D: simultaneous extracellular and whole cell recordings of evoked and 
spontaneous activities in epileptic slices obtained from the contralateral hippocampus after mirror focus formation. Note that bumetanide blocked interictal-like 
epileptiform events (B) but did not completely block the excitatory action of GABA (C and D). Resting membrane potentials (Em) measured with single 
NMDA receptor channels (E) and DFGABA measured with single GABAA receptor channels (F) in control and epileptic slices. 
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